InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,646.07
(
1.20%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DonShimoda

Send PM Follow Ignore
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

DonShimoda

Re: JJM760 post# 14880

Monday, 12/12/2011 11:37:31 AM

Monday, December 12, 2011 11:37:31 AM

Post# of 80490
It's hard for me to come up with a $400mm peak sales scenario that's realistic. If sprycel/tasigna continue to take 1st line market share, pona will end up capturing an even greater share of the 2nd line market which is approaching $1 billion, today. Even if gleevec (or its generic) is able to maintain its first line market share, the anticipated confirmatory study should position pona well in 1st line high-risk pts in addition to T315I which, combined with high-risk pts, could readily generate 400MM alone.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up